Cure8 research brief
The findings suggest that over three decades more patients receive medical prevention after ileocolic resection — including thiopurines and biologics — and that rates of needing a second surgery have fallen. This matters to people with Crohn’s disease facing surgery or postoperative management decisions.
Adults with Crohn’s disease who have had or will have ileocolic resection, post-surgery patients, gastroenterologists and colorectal surgeons, and researchers studying postoperative recurrence strategies.
This study used data from the Spanish ENEIDA registry to compare three time periods (1990–2000, 2000–2010, 2011–2020) for adults having a first ileocolic resection for Crohn’s disease.
Use of medical prevention after surgery rose over time — thiopurines and biologic therapies became more commonly used — and the proportion treated with biologics for postoperative recurrence also increased.
The authors report higher surgical postoperative-recurrence–free survival at 5 and 10 years in the eras after biologics became available compared with the pre-biologic era. The report summarizes registry observational data rather than a randomized trial.
It describes time trends in treatment and associated changes in the cumulative probability of needing a second surgery, without proving causation. Clinical details such as selection for postoperative prevention, specific biologic agents used in each patient group, dosing, and adverse events are not detailed in this brief abstract.
If you are a patient who has had surgery for Crohn’s disease and are discussing postoperative prevention options with your clinician, this study supports that routine use of immunomodulators and biologics has increased and that surgical recurrence rates have fallen over time in this registry. Treatment decisions should be individualized with your care team.
This is an observational registry analysis (ENEIDA) comparing historical eras; associations over time do not establish that increased biologic use alone caused lower surgical recurrence. The abstract does not provide randomized comparisons, detailed adverse-event data, or individual-level treatment allocation criteria.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
This study suggests that regional differences in how often and how early advanced drugs are used didn’t change 10-year rates of surgery, hospitalization, or progression to complicated Crohn’s disease in this cohort.
